TY  - GEN
AU  - Manso,Luis
AU  - Moreno Antón,Fernando
AU  - Izarzugaza Perón,Yann
AU  - Delgado Mingorance,Juan I
AU  - Borrega García,Pablo
AU  - Echarri González,María J
AU  - Martínez-Jañez,Noelia
AU  - López-González,Ana
AU  - Olier Garate,Clara
AU  - Ballesteros García,Anabel
AU  - Chacón López-Muñíz,Ignacio
AU  - Ciruelos Gil,Eva
AU  - García-Sáenz,Jose Angel
AU  - Paz-Ares,Luis
TI  - Safety of eribulin as third-line chemotherapy in HER2-negative, advanced breast cancer pre-treated with taxanes and anthracycline: OnSITE study
SN  - 1524-4741
PY  - 2019///1202
KW  - Aged
KW  - Anthracyclines
KW  - administration & dosage
KW  - Antineoplastic Agents
KW  - adverse effects
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - therapeutic use
KW  - Breast Neoplasms
KW  - drug therapy
KW  - Disease-Free Survival
KW  - Female
KW  - Furans
KW  - Humans
KW  - Ketones
KW  - Middle Aged
KW  - Neoplastic Cells, Circulating
KW  - Prospective Studies
KW  - Receptor, ErbB-2
KW  - metabolism
KW  - Taxoids
N1  - Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
UR  - https://doi.org/10.1111/tbj.13199
ER  -